Last reviewed · How we verify
Assess AAA rupture risk by PET-CTA scans
Assess AAA rupture risk by PET-CTA scans is a Small molecule drug developed by Washington University School of Medicine. It is currently FDA-approved for Risk stratification of abdominal aortic aneurysm (AAA) for rupture prediction.
This is a diagnostic imaging protocol using PET-CTA (positron emission tomography combined with computed tomography angiography) to assess the risk of abdominal aortic aneurysm (AAA) rupture.
This is a diagnostic imaging protocol using PET-CTA (positron emission tomography combined with computed tomography angiography) to assess the risk of abdominal aortic aneurysm (AAA) rupture. Used for Risk stratification of abdominal aortic aneurysm (AAA) for rupture prediction.
At a glance
| Generic name | Assess AAA rupture risk by PET-CTA scans |
|---|---|
| Sponsor | Washington University School of Medicine |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
PET-CTA combines metabolic imaging (PET) with anatomical imaging (CTA) to evaluate both the structural dimensions of an abdominal aortic aneurysm and its metabolic activity, which may indicate inflammation and instability. This multimodal approach helps clinicians stratify rupture risk and guide treatment decisions, distinguishing stable from high-risk aneurysms that may require intervention.
Approved indications
- Risk stratification of abdominal aortic aneurysm (AAA) for rupture prediction
Common side effects
- Radiation exposure from PET and CT imaging
- Contrast-related nephropathy (from CTA contrast agent)
- Allergic reaction to radiopharmaceutical or contrast
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Assess AAA rupture risk by PET-CTA scans CI brief — competitive landscape report
- Assess AAA rupture risk by PET-CTA scans updates RSS · CI watch RSS
- Washington University School of Medicine portfolio CI
Frequently asked questions about Assess AAA rupture risk by PET-CTA scans
What is Assess AAA rupture risk by PET-CTA scans?
How does Assess AAA rupture risk by PET-CTA scans work?
What is Assess AAA rupture risk by PET-CTA scans used for?
Who makes Assess AAA rupture risk by PET-CTA scans?
What development phase is Assess AAA rupture risk by PET-CTA scans in?
What are the side effects of Assess AAA rupture risk by PET-CTA scans?
Related
- Manufacturer: Washington University School of Medicine — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Risk stratification of abdominal aortic aneurysm (AAA) for rupture prediction
- Compare: Assess AAA rupture risk by PET-CTA scans vs similar drugs
- Pricing: Assess AAA rupture risk by PET-CTA scans cost, discount & access